Plasmodium vivax malaria, a leading health problem throughout the Amazon basin on Latin America, is endemic in the Peruvian Amazon. The long-term goal of this project is to determine specific epidemiological characteristics of P. vivax transmission and human reservoirs of maintaining P. vivax transmission in the Peruvian Amazon region towards the rational deployment of a transmission-blocking vaccine. This project will test the hypothesis that reproduction of exogenous P. vivax into local populations is responsible for continuing transmission in rural villages surrounding Iquitos, Peru, the capital of the Peruvian Amazon. Alternative hypotheses are 1) that relapsing P. vivax malaria is the source for maintaining local transmission;or 2) there is simply continuous transmission of already locally established genotypes within local populations.
Specific aim 1 is to determine circulating Plasmodium vivax genotypes at the individual village level through prospective, population-based surveillance of people with P. vivax parasitemia. Changes or stability of P. vivax genotypes will be assessed over space and time using recently validated genetic markers.
Specific aim 2 is to determine transmission dynamics of P. vivax using geographic spatio- temporal analysis of circulating genotypes using spatial statistical modeling and cluster analysis. These analyses will distinguish whether circulating P. vivax genotypes are already established in villages (either continuously circulating or resulting from relapsing P. vivax from hypnozoites) or are newly introduced by infected inhabitants returning from travel away from the village.
Specific aim 3 is to determine whether transmission-blocking immunity develops in the Peruvian Amazon population to potentially modify P. vivax transmission dynamics. Membrane feeding studies will be performed using local Anopheles darlingi mosquitoes and local P. vivax patients as sources of parasites, and by experimental infections of Anopheles mosquitoes from splenectomized non-human primates infected experimentally with P. vivax. In vitro assays (ELISA, IFA) will be used to determine the validity of the in vivo mosquito infection assay. These data will provide the basis for planning transmission-blocking interventions and elimination of human reservoirs of P. vivax, and provide a rational basis for determining strategies to implement and deploy new transmission- blocking vaccines as one approach towards the future elimination of P. vivax malaria from the Amazon basin.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI067727-04
Application #
7635870
Study Section
Special Emphasis Panel (ZRG1-CRFS-C (01))
Program Officer
Rao, Malla R
Project Start
2006-07-15
Project End
2011-06-30
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
4
Fiscal Year
2009
Total Cost
$605,522
Indirect Cost
Name
University of California San Diego
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
White, Sara E; Harvey, Steven A; Meza, Graciela et al. (2018) Acceptability of a herd immunity-focused, transmission-blocking malaria vaccine in malaria-endemic communities in the Peruvian Amazon: an exploratory study. Malar J 17:179
Muela Ribera, Joan; Hausmann-Muela, Susanna; Gryseels, Charlotte et al. (2016) Re-imagining adherence to treatment from the ""other side"": local interpretations of adverse anti-malarial drug reactions in the Peruvian Amazon. Malar J 15:136
Manrique, Paulo; Hoshi, Mari; Fasabi, Manuel et al. (2015) Assessment of an automated capillary system for Plasmodium vivax microsatellite genotyping. Malar J 14:326
Rosas-Aguirre, Angel; Ponce, Oscar J; Carrasco-Escobar, Gabriel et al. (2015) Plasmodium vivax malaria at households: spatial clustering and risk factors in a low endemicity urban area of the northwestern Peruvian coast. Malar J 14:176
Torres, Katherine J; Castrillon, Carlos E; Moss, Eli L et al. (2015) Genome-level determination of Plasmodium falciparum blood-stage targets of malarial clinical immunity in the Peruvian Amazon. J Infect Dis 211:1342-51
Patra, Kailash P; Li, Fengwu; Carter, Darrick et al. (2015) Alga-produced malaria transmission-blocking vaccine candidate Pfs25 formulated with a human use-compatible potent adjuvant induces high-affinity antibodies that block Plasmodium falciparum infection of mosquitoes. Infect Immun 83:1799-808
Chuquiyauri, Raul; Molina, Douglas M; Moss, Eli L et al. (2015) Genome-Scale Protein Microarray Comparison of Human Antibody Responses in Plasmodium vivax Relapse and Reinfection. Am J Trop Med Hyg 93:801-9
Yalcindag, Erhan; Rougeron, Virginie; Elguero, Eric et al. (2014) Patterns of selection on Plasmodium falciparum erythrocyte-binding antigens after the colonization of the New World. Mol Ecol 23:1979-93
Torres, Katherine J; Villasis, Elizabeth; Bendezú, Jorge et al. (2014) Relationship of regulatory T cells to Plasmodium falciparum malaria symptomatology in a hypoendemic region. Malar J 13:108
Chuquiyauri, Raul; Peñataro, Pablo; Brouwer, Kimberly C et al. (2013) Microgeographical differences of Plasmodium vivax relapse and re-infection in the Peruvian Amazon. Am J Trop Med Hyg 89:326-38

Showing the most recent 10 out of 25 publications